Fig. 4: Improvements in time to first episode of asthma worsening in patients in the PrimoTinA-, MezzoTinA- and GraziaTinA-asthma trials receiving tiotropium add-on therapy compared with placebo.
From: Asthma exacerbations and worsenings in patients aged 1–75 years with add-on tiotropium treatment
Comparison of number of adults with asthma receiving either tiotropium (5 or 2.5 µg) or placebo once-daily reporting at least one episode of asthma worsening. The vertical axis represents an equal risk of experiencing an episode of asthma worsening when receiving either placebo or tiotropium. HR values <1 demonstrate that tiotropium provides a reduction in risk compared with placebo. An upper CI of <1 demonstrates that the reduction in risk is statistically significant. CI confidence interval, HR hazard ratio.
